ResearcherThe University of SydneyNo recent work listed
Aiqun Xue
Matched on OpenAlex author ID A5112904725. Sources: OpenAlex.
Their work
- Papers
- 6 (first author 4, last author 0)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 9
2012: 1 paper · 2013: none · 2014: 1 paper · 2015: none · 2016: 2 papers · 2017: none · 2018: none · 2019: none · 2020: 2 papers
Papers 6
- Biomimetic Gemcitabine-Lipid Prodrug Nanoparticles for Pancreatic Cancer. First author DOI 10.1002/cplu.202000253↗
- Pancreatic adenocarcinoma preferentially takes up and is suppressed by synthetic nanoparticles carrying apolipoprotein A-II and a lipid gemcitabine prodrug in … Co-author DOI 10.1016/j.canlet.2020.08.045↗
- Upstream and Downstream Co-inhibition of Mitogen-Activated Protein Kinase and PI3K/Akt/mTOR Pathways in Pancreatic Ductal Adenocarcinoma. First author DOI 10.1016/j.neo.2016.06.001↗
- Apolipoprotein A-II Plus Lipid Emulsion Enhance Cell Growth via SR-B1 and Target Pancreatic Cancer In Vitro and In Vivo. First author DOI 10.1371/journal.pone.0151475↗
- Cotargeting of epidermal growth factor receptor and PI3K overcomes PI3K-Akt oncogenic dependence in pancreatic ductal adenocarcinoma. First author DOI 10.1158/1078-0432.ccr-13-3377↗
- Discovery of diagnostic biomarkers for pancreatic cancer in immunodepleted serum by SELDI-TOF MS. Co-author DOI 10.1016/j.pan.2012.02.009↗
Closest collaborators
The 9 strongest of 9 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Ross C. Smith · 6 shared papers, 2012–2020 · strength 0.43
- Paper Biomimetic Gemcitabine-Lipid Prodrug Nanoparticles for Pancreatic Cancer. DOI 10.1002/cplu.202000253↗
- Paper Pancreatic adenocarcinoma preferentially takes up and is suppressed by synthetic nanoparticles carrying apolipoprotein … DOI 10.1016/j.canlet.2020.08.045↗
- Paper Upstream and Downstream Co-inhibition of Mitogen-Activated Protein Kinase and PI3K/Akt/mTOR Pathways in Pancreatic Duct… DOI 10.1016/j.neo.2016.06.001↗
- Sohel M. Julovi · 4 shared papers, 2014–2020 · strength 0.32
- Paper Biomimetic Gemcitabine-Lipid Prodrug Nanoparticles for Pancreatic Cancer. DOI 10.1002/cplu.202000253↗
- Paper Pancreatic adenocarcinoma preferentially takes up and is suppressed by synthetic nanoparticles carrying apolipoprotein … DOI 10.1016/j.canlet.2020.08.045↗
- Paper Apolipoprotein A-II Plus Lipid Emulsion Enhance Cell Growth via SR-B1 and Target Pancreatic Cancer In Vitro and In Vivo. DOI 10.1371/journal.pone.0151475↗
- Jerikho C. Bulanadi · 3 shared papers, 2016–2020 · strength 0.28
- Paper Biomimetic Gemcitabine-Lipid Prodrug Nanoparticles for Pancreatic Cancer. DOI 10.1002/cplu.202000253↗
- Paper Pancreatic adenocarcinoma preferentially takes up and is suppressed by synthetic nanoparticles carrying apolipoprotein … DOI 10.1016/j.canlet.2020.08.045↗
- Paper Apolipoprotein A-II Plus Lipid Emulsion Enhance Cell Growth via SR-B1 and Target Pancreatic Cancer In Vitro and In Vivo. DOI 10.1371/journal.pone.0151475↗
- Minoo J. Moghaddam · 3 shared papers, 2016–2020 · strength 0.28
- Paper Biomimetic Gemcitabine-Lipid Prodrug Nanoparticles for Pancreatic Cancer. DOI 10.1002/cplu.202000253↗
- Paper Pancreatic adenocarcinoma preferentially takes up and is suppressed by synthetic nanoparticles carrying apolipoprotein … DOI 10.1016/j.canlet.2020.08.045↗
- Paper Apolipoprotein A-II Plus Lipid Emulsion Enhance Cell Growth via SR-B1 and Target Pancreatic Cancer In Vitro and In Vivo. DOI 10.1371/journal.pone.0151475↗
- Anthony James Gill · 3 shared papers, 2014–2020 · strength 0.20
- Paper Pancreatic adenocarcinoma preferentially takes up and is suppressed by synthetic nanoparticles carrying apolipoprotein … DOI 10.1016/j.canlet.2020.08.045↗
- Paper Apolipoprotein A-II Plus Lipid Emulsion Enhance Cell Growth via SR-B1 and Target Pancreatic Cancer In Vitro and In Vivo. DOI 10.1371/journal.pone.0151475↗
- Paper Cotargeting of epidermal growth factor receptor and PI3K overcomes PI3K-Akt oncogenic dependence in pancreatic ductal a… DOI 10.1158/1078-0432.ccr-13-3377↗
- Nick Pavlakis · 2 shared papers, 2014–2016 · strength 0.12
- Paper Upstream and Downstream Co-inhibition of Mitogen-Activated Protein Kinase and PI3K/Akt/mTOR Pathways in Pancreatic Duct… DOI 10.1016/j.neo.2016.06.001↗
- Paper Cotargeting of epidermal growth factor receptor and PI3K overcomes PI3K-Akt oncogenic dependence in pancreatic ductal a… DOI 10.1158/1078-0432.ccr-13-3377↗
- Matthew H. Wong · 2 shared papers, 2014–2016 · strength 0.12
- Paper Upstream and Downstream Co-inhibition of Mitogen-Activated Protein Kinase and PI3K/Akt/mTOR Pathways in Pancreatic Duct… DOI 10.1016/j.neo.2016.06.001↗
- Paper Cotargeting of epidermal growth factor receptor and PI3K overcomes PI3K-Akt oncogenic dependence in pancreatic ductal a… DOI 10.1158/1078-0432.ccr-13-3377↗
- Jaswinder Singh Samra · 1 shared paper, 2014 · strength 0.04
- Robert C. Gandy · 1 shared paper, 2012 · strength 0.04
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.